Ronald Eisenstein is the co-leader of the Patents Practice Group at Nixon Peabody. Mr. Eisenstein focuses his practice on life sciences and intellectual property counseling. He is also a member of the firm’s Life Sciences Steering Committee.
Mr. Eisenstein has extensive experience in prosecuting biotechnology, medical, and chemical cases, and counseling with respect to strategic management of the intellectual property portfolios. Mr. Eisenstein advises clients in developing and implementing patent strategies including strategic patent procurement, portfolio development, competitive intelligence and analysis, licensing and enforcement of the patents. He assists clients in understanding and effectively using post-issuance procedures such as oppositions and interferences both offensively and defensively. He has provided freedom-to-operate guidance to clients as well as due diligence for acquisitions and financing.
His work has involved the areas of personalized medicine including diagnostics, proteomics, biomarkers, companion diagnostics and related systems; cancer vaccines, immune modulation, stem cells, gene therapy, angiogenesis modulation, signal transduction and primate lentiviruses.
Mr. Eisenstein has been actively involved in patent litigation in federal district courts throughout the United States.
Recent Publications and Speaking Engagements
Mr. Eisenstein has lectured and written extensively on interferences, oppositions, stem cells, personalized medicine, and living with and successfully managing patent portfolios with respect to changing court precedents, PTO rules and regulations, and patent reform including:
- “Understanding Patent Reform and Leading Patent Developments,” France Biotech—Paris, France, 2011;
- “From Discovery To Therapy: What Every Researcher Should Know About Technology Transfer And Drug Development;” Symposium on Advanced Wound Care/Wound Healing Society - 24th Annual Symposium on Advanced Wound Care—Dallas, 2011;
- “Personalized Medicine,” Personalized Medicine World Conference—Silicon Valley, 2011;
- “Dealing with the Attack on The Patentability of Personalized Medicine and Diagnostic Patent,” Association of University Technology Managers (AUTM) Annual Meeting—New Orleans, 2010;
- “What is Due Diligence Analysis?” 17th Annual Advanced Licensing Institute at Franklin Pierce Law Center—Concord, 2009;
- “Global Patenting Issues: Interferences;” Association of University and Technology Managers (AUTM) Annual Meeting—San Diego, 2008;
- “SMART Patenting: Dealing With Interferences and Oppositions in a Global Society,” and “Surviving Patent Reform;” New York Biotech Association’s (NYBA) Annual Meeting—New York, 2007;
- “Ethical Oppositions,” BIO Annual Meeting—Chicago, 2006.